Which psychosocial factors are related to chelation adherence in thalassemia a systematic review

Hemoglobin

Volumn 34, Issue 3, 2010, Pages 305-321

  Evangeli, Michael ^a   Mughal, Kulsoom ^a   Porter, John B ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adherence; Chelation; Psychosocial; Systematic review; Thalassemia

Indexed keywords

DEFEROXAMINE;

CHELATION THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DEMOGRAPHY; ETHNICITY; EXTERNAL VALIDITY; HUMAN; INTERNAL VALIDITY; IRON OVERLOAD; METHODOLOGY; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; REVIEW; SELF REPORT; SICKLE CELL ANEMIA; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; THALASSEMIA;

CHELATION THERAPY; DEMOGRAPHY; HUMANS; IRON CHELATING AGENTS; MEDICATION ADHERENCE; THALASSEMIA;

EID: 77953239810     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2010.485080     Document Type: Review

References (28)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-761.
2. Atkin K, Ahmad WI. Family care-giving and chronic illness: how patients cope with a child with sickle cell disorder or thalassaemia. Health Soc Care Community. 2000;8(1):57-69.
3. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003;10(12):1065-1076.
4. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther. 2007;29(5):909-917.
5. Vullo C, Di Palma A. Compliance with therapy in Cooley's anaemia. Prog Clin Biol Res. 1989;309:43-49.
6. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573.
7. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
8. Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes. 2006;4:73.
9. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051- 2052.
10. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 2002;15(2):329-368.
11. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10): 1187-1193.
12. Matsui D, Hermann C, Klein J, et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol. 1994;34(9): 944-949.
13. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919-1929.
14. Amico KR, Toro-Alfonso J, Fisher JD. An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence. AIDS Care. 2005;17(6):661-673.
15. Patterson JM, Budd J, Goetzz D, Warwick WJ. Family correlates of a 10-year pulmonary health trend in cystic fibrosis. Pediatrics. 1993;91(2):383-389.
16. Siegfried N, Muller M, Volmink J, et al. Male circumcision for prevention of heterosexual acquisition of HIV in men (Review). Cochrane Database Sysst Rev. 2008;4.
17. Ward A, Caro JJ, Green TC. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol. 2002;2:3.
18. Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol. 2001;56(12):915-922.
19. Rosenstock LM. The health belief model and preventative health behaviour. Health Education Monographs. 1974;2(4):354-386.
20. Ajzen I, Fishbein M. Understanding Attitudes and Social Behavior. Engelwood Cliffs: Prentice Hall. 1980.
21. Johnson MJ. The medication adherence model: a guide for assessing medication taking. Res Theory Nurs Pract. 2002;16(3):179-192.
22. Di Palma A, Barrai I, Candini G, Vullo C. Compliance alia terapia chelante dei soggeti affeti di Cooley. Riv Ital Ped. 1982;8183-8187
23. Beratis S. Noncomliance with iron chelation therapy in patients with thalassaemia. J Psychosom Res. 1989;33(6):739-745.
24. Koch DA, Giardina PJ, Ryan M, MacQueen M, Hilgartner MW. Behavioral contracting to improve adherence in patients with thalassemia. J Pediatr Nurs. 1993;8(2):106-111.
25. Goldbeck L, Baving A, Kohne E. Psychosocial aspects of β-thalassemia: distress, coping and adherence. (German) Klin Padiatr. 2000;212(5):354-1259
26. Treadwell MJ, Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Semin Hematol. 2001;38(1, Suppl. 1):77-84.
27. Aydinok Y, Erermis S, Bukusoglu N, Yilmaz D, Solak U. Psychosocial implications of thalassemia major. Pediatr Int. 2005;47(1):84-89.
28. Treadwell MJ, Law AW, Sung J, et al. Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer. 2005;44(5):500-507.